| Product NDC: | 21695-866 |
| Proprietary Name: | Amlobenz |
| Non Proprietary Name: | Amlobenz |
| Active Ingredient(s): | 5; 10 mg/1; mg/1 & nbsp; Amlobenz |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 21695-866 |
| Labeler Name: | Rebel Distributors Corp |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA077183 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20100419 |
| Package NDC: | 21695-866-90 |
| Package Description: | 90 CAPSULE in 1 BOTTLE (21695-866-90) |
| NDC Code | 21695-866-90 |
| Proprietary Name | Amlobenz |
| Package Description | 90 CAPSULE in 1 BOTTLE (21695-866-90) |
| Product NDC | 21695-866 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Amlobenz |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 20100419 |
| Marketing Category Name | ANDA |
| Labeler Name | Rebel Distributors Corp |
| Substance Name | AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE |
| Strength Number | 5; 10 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Calcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [Chemical/Ingredient],Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE] |